Weekly somapacitan efficacy matches daily rhGH over 3 years in GHD
The 3-year findings of the REAL 3 trial show that weekly somapacitan continued to deliver equivalent height gains and safety results to that achieved with standard daily recombinant human growth hormone treatment in children with growth hormone deficiency.




